Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Alumis Inc. Common StockNASDAQ: ALMS

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA remains negative

Q2 FY2026 EBITDA was -$148.78M, compared with -$119.97M a year earlier. Trailing-twelve-month EBITDA was -$442.87M.

Context

  • EBITDA amounted to 1032.8% of revenue in FY2025.
  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 8 analysts of -$2.76B (-1012.3%) for the fiscal year ending Dec 2026, a slowdown from the +14.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$148.78M-61.4% QoQ
Last fiscal yearDec 2025
-$248.39M+14.7% YoY
LTMJun 2026
-$442.87M-9.5% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.0%+11.6%+35.6 pp
1 year+14.7%-1012.3%-1027.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(248.39M) USD
Year-over-year change
+14.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ALMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.5% is the 5th highest of 10, against a peer median of -26.7%.
  • EBITDA amounts to 5986.3% of revenue for ALMS, versus a peer median of 843.9%.
ALMS Competitors
EBITDA for ALMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$131.28M USD+170.9%—43.8%
ANABAnaptysBio, Inc.LTM Mar 2026$58.49M USD+176.6%—25.2%
TLSATiziana Life Sciences LtdFY2025-$21.05M USD-26.7%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$25.22M USD+54.6%——
IFRXInflaRx N.V.LTM Mar 2026-€42.36M EUR+1.6%—144435.8%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024-€45.89M EUR-286.3%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$70.61M USD-31.5%—843.9%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$84.35M USD-214.9%—142957.6%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$84.44M USD-35.4%——
ALMSAlumis Inc. Common StockLTM Jun 2026-$442.87M USD-9.5%—5986.3%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ALMS) —-26.7%—843.9%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00024.05M
Cost of Revenue250K03.15M3.5M
Gross Profit(250K)0(3.15M)20.55M
Gross Margin———85.5%
Research & Development101.05M137.68M265.55M386M
Selling, General & Admin12.55M20.5M35.2M91.86M
Operating Expenses113.6M158.17M297.6M447.76M
Depreciation & Amortization250K1.28M3.15M3.5M
EBITDA(111.68M)(153.71M)(291.08M)(248.39M)
EBITDA Margin———-1032.8%
Operating Income(113.85M)(158.17M)(300.75M)(427.2M)
Operating Margin———-1776.3%
Interest Income1.99M3.37M12.02M14.18M
Interest Expense0000
Other Income / Expenses1.92M3.18M6.52M175.32M
Income Before Tax(111.93M)(154.99M)(294.23M)(251.89M)
Pre-Tax Margin———-1047.3%
Income Tax Expense000(8.56M)
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Net Margin———-1011.7%
EPS (Basic)(14.93)(2.99)(10.38)(2.32)
EPS (Diluted)(14.93)(2.99)(10.38)(2.32)
Weighted Avg Shares7.5M51.84M28.34M850.3M
Weighted Avg Shares (Diluted)7.5M51.84M28.34M850.3M

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.